Biomaterials for enhancing anti-cancer immunity.

[1]  D. Irvine,et al.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles , 2011, Proceedings of the National Academy of Sciences.

[2]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[3]  Gang Wu,et al.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity , 2016, Oncoimmunology.

[4]  David J Mooney,et al.  Injectable, porous, and cell-responsive gelatin cryogels. , 2014, Biomaterials.

[5]  D. Irvine,et al.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. , 2011, Biomaterials.

[6]  D. Mooney,et al.  Engineered Materials for Cancer Immunotherapy. , 2015, Nano today.

[7]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[8]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[9]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[10]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[11]  J. Hubbell,et al.  Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose , 2013, Proceedings of the National Academy of Sciences.

[12]  J. Hubbell,et al.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination , 2011, Proceedings of the National Academy of Sciences.

[13]  D. Irvine,et al.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. , 2012, Biomaterials.

[14]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[15]  J. Moon,et al.  Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy , 2015, Vaccines.

[16]  David J Mooney,et al.  Injectable preformed scaffolds with shape-memory properties , 2012, Proceedings of the National Academy of Sciences.

[17]  J. Hubbell,et al.  Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014, Cancer Immunology Research.

[18]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[19]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[20]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[21]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[22]  D. Irvine,et al.  Engineering New Approaches to Cancer Vaccines , 2015, Cancer Immunology Research.

[23]  F. Pijpers,et al.  Therapeutic cancer vaccines , 2005, Nature Reviews Drug Discovery.

[24]  M. Bureau,et al.  Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors , 2013, Science Translational Medicine.

[25]  Yifan Ma,et al.  PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[27]  David J Mooney,et al.  Injectable cryogel-based whole-cell cancer vaccines , 2015, Nature Communications.

[28]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[29]  Gregory L. Szeto,et al.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. , 2015, The Journal of clinical investigation.

[30]  Richard A Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[31]  Nicholas A Peppas,et al.  Hydrogels and Scaffolds for Immunomodulation , 2014, Advanced materials.

[32]  S. B. Stephan,et al.  Biopolymer implants enhance the efficacy of adoptive T cell therapy , 2014, Nature Biotechnology.

[33]  J. Ramsey,et al.  The role of the lymphatic system in vaccine trafficking and immune response. , 2011, Advanced drug delivery reviews.

[34]  Darrell J Irvine,et al.  In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[35]  D. Irvine,et al.  Synthetic Nanoparticles for Vaccines and Immunotherapy. , 2015, Chemical reviews.

[36]  K Dane Wittrup,et al.  Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. , 2013, Cancer research.

[37]  David J Mooney,et al.  Macroscale delivery systems for molecular and cellular payloads. , 2013, Nature materials.

[38]  D. Irvine,et al.  Membrane Anchored Immunostimulatory Oligonucleotides for In Vivo Cell Modification and Localized Immunotherapy** , 2011, Angewandte Chemie.

[39]  Y. Takakura,et al.  Induction of Potent Antitumor Immunity by Sustained Release of Cationic Antigen from a DNA‐Based Hydrogel with Adjuvant Activity , 2015 .

[40]  C. Löwik,et al.  Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[41]  J. DeSimone,et al.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. , 2015, Molecular pharmaceutics.

[42]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[43]  K. Leong,et al.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. , 2012, Nature materials.

[44]  David J Mooney,et al.  Inflammatory Cytokines Presented from Polymer Matrices Differentially Generate and Activate DCs In Situ , 2013, Advanced functional materials.

[45]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[46]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[47]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[48]  M. Swartz,et al.  Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity , 2012, Nature Reviews Cancer.

[49]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[50]  David L Porter,et al.  Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.

[51]  D. Irvine,et al.  Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination , 2013, Science Translational Medicine.

[52]  David J Mooney,et al.  Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. , 2014, Cancer research.

[53]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.